Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for
COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory …

The concept of coronavirus disease 2019 (COVID-19)-related cytokine storm syndrome
(COVID-CSS) emerged early in the severe acute respiratory syndrome coronavirus 2 (SARS …

Interleukin‐6 (IL‐6)–mediated hyperinflammation may contribute to the mortality of
coronavirus disease 2019 (COVID‐19). The IL‐6 receptor–blocking monoclonal antibody …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
challenged medicine and health care on a global scale. Its impact and frightening mortality …

Around the tenth day after diagnosis,∼ 20% of patients with coronavirus disease 2019
(COVID-19)− associated pneumonia evolve toward severe oxygen dependence (stage 2b) …

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2),
emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease …

The detection and control of pro-inflammatory response is crucial in the early stages of viral
infection. Coronavirus disease 2019 (COVID-19) is an emerging viral disease of global …

COVID-19 has emerged as a global pandemic. It is mainly manifested as pneumonia which
may deteriorate into severe respiratory failure. The major hallmark of the disease is the …

The recently public health crises in the world is emerged by spreading the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) also named COVID-19. The virus is …